^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1m
    A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    In murine xenotransplant myeloma models, giving APRIL during the first week after infusion of BCMA CAR T-cells increased IFNγ-positive CAR T-cells in the tumor tissues, and enhanced the anti-tumor effect of CAR T-cell. In conclusion, APRIL counteracted the actions of sBCMA in BCMA CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of BCMA CAR T-cell therapies.
    Journal
    |
    IFNG (Interferon, gamma)
    1m
    A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, The Affiliated Hospital of Qingdao University
    New P1 trial • IO biomarker
    1m
    RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    2ms
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, BrightPath Biotherapeutics Co., Ltd.
    New P1 trial
    2ms
    CAR-T Cells Targeting Autoimmune Diseases (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Jun 2026 --> Dec 2030 | Trial primary completion date: Jul 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    2ms
    CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2029 --> Mar 2027
    Trial completion date • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel)
    2ms
    KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel)
    2ms
    Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, The First Affiliated Hospital of Soochow University
    New P1 trial
    2ms
    RN1201 Injection in the Treatment of Antibody-Mediated Diseases (clinicaltrials.gov)
    P1, N=9, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    CADMIUM: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma (clinicaltrials.gov)
    P2, N=78, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Abecma (idecabtagene vicleucel) • iberdomide (CC-220)
    2ms
    A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study. (PubMed, Blood)
    These results suggest that CAR-NKG2A technology may overcome HvGR, especially in patients with elevated NKG2A expression on NK cells. Further studies of CT0590 in RRMM and pPCL are warranted.
    P1 data • Preclinical • Journal • IO biomarker • First-in-human
    |
    KLRC1 (Killer Cell Lectin Like Receptor C1)
    2ms
    Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma. (PubMed, Blood)
    Finally, validating functional relevance, pharmacologic inhibition of NF-κB abrogated CAR-T cytotoxicity and cytokine production in vitro. Our results support that NFKB in the ide-cel product marks a signaling axis impacting CAR-T function and NFKB activity represents a global marker of T cell fitness present prior to CAR-T manufacture.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    Abecma (idecabtagene vicleucel)